CSRxP: PASSAGE OF CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS WOULD BE POSITIVE STEPS TOWARD HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE
Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent… Read More

Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent… Read More
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse… Read More
Congress Should Not Further Consider Misguided Proposal That Would Enable More… Read More
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
Legislation Scheduled for Thursday Markup Would Encourage Adoption of… Read More
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
Letter Encourages Lawmakers to Advance Bipartisan Solutions to Hold Big Pharma… Read More
Campaign Will Add Support to Growing Bipartisan Momentum to Crack Down on Big… Read More
Lowering Prices for Some Patients at Some Dosages Will Have Limited Impact,… Read More